Literature DB >> 12095379

Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners.

Richard E Chaisson, Joan Armstrong, John Stafford, Jonathan Golub, Sarah Bur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12095379     DOI： 10.1001/jama.288.2.165

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

1.  N'-[(E)-2-Meth-oxy-benzyl-idene]pyrazine-2-carbohydrazide.

Authors:  Marcus V N de Souza; Camilo H da Silva Lima; James L Wardell; Solange M S V Wardell; Edward R T Tiekink
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-06-18

2.  Predictors of latent tuberculosis infection treatment completion in the United States: an inner city experience.

Authors:  Y Hirsch-Moverman; J Bethel; P W Colson; J Franks; W El-Sadr
Journal:  Int J Tuberc Lung Dis       Date:  2010-09       Impact factor: 2.373

3.  N'-[(E)-2,6-Dichloro-benzyl-idene]pyrazine-2-carbohydrazide.

Authors:  R Alan Howie; Marcus V N de Souza; Solange M S V Wardell; James L Wardell; Edward R T Tiekink
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-12-16

4.  N-(4-Bromo-phen-yl)pyrazine-2-carbox-amide.

Authors:  Marcelle de Lima Ferreira; Marcus V N de Souza; Solange M S V Wardell; James L Wardell; Edward R T Tiekink
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-10-09

5.  N-(2-Chloro-eth-yl)pyrazine-2-carboxamide.

Authors:  Camilo H da Silva Lima; Marcus V N de Souza; Solange M S V Wardell; James L Wardell; Edward R T Tiekink
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-10-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.